June 24, 2026
Brian Reid and Peter J. Neumann
Much of the attention around the 340B drug discount program highlights the limited evidence that eligible hospitals and clinics actually use the revenue the program generates to improve patient care or affordability for vulnerable Americans. There has been less consideration of the second-order effects on how the program is financed, particularly the way 340B providers can “intercept” discounts that would otherwise lower costs elsewhere in the healthcare system.
The 340B program imposes different costs on different parts of the system. Many of the dollars that flow to 340B hospitals and clinics would have otherwise accrued to employers, health plans, and state Medicaid programs, allowing those entities to control premiums or expand benefits.
In this article, we examine the way in which 340B has created financial winners and losers and offer recommendations on transparency-focused reforms designed to clarify the impact of 340B on other health system elements.
340B's Rapid Rise
The 340B program has expanded substantially over the past decade, with sales growing from $9 billion a decade ago to $82 billion in 2024. What was once an obscure program is now the subject of fierce statehouse battles and sharp-tongued newspaper editorials.
The program benefits eligible hospitals and clinics by allowing them to buy medicines directly from manufacturers at low prices, sometimes as little as a penny. These medicines are typically used to treat fully insured patients, and providers can seek full reimbursement from insurance companies, generating revenue from the spread between the 340B price and the full reimbursement amount. That additional revenue generated by eligible entities can be substantial; one hospital in Minnesota generated more than $300 million in net revenue from the 340B program in a single year.
Overlapping Discounts
The drug supply chain is built on rebates and other discounts. Drug manufacturers offer commercial payers and Medicare plans rebates in return for improved access to certain medicines. State Medicaid programs receive mandated discounts – generally Medicaid must receive either the best price available in the market or a set minimum discount of 23.1%.
These pricing concessions exist alongside 340B rebates. Thus, a single prescription could be eligible for more than one markdown, an issue known as “duplicative discounts.” For example, a commercially insured patient’s health plan may demand a manufacturer rebate when a certain medicine is used. But if that medicine is linked to a 340B hospital, the prescription would also be eligible for a 340B discount.
There are a series of guardrails designed to protect against duplicative discounts. For example, by law, Medicaid forbids duplicative discounts, and medicines where the “Maximum Fair Price” under the Medicare Price Drug Negotiation Program is paid are not subject to 340B discounts. In commercial plans, contracts often forbid payers from seeking a rebate for a medicine that has already received a 340B discount.
Impacts on Employers and Medicaid
The ban on duplicative discounts means that employer health plans will generally forgo a rebate when a patient receives a medicine linked to a 340B provider. The provider receives the 340B discount, and the health plan cannot receive the contracted rebate to which it would otherwise have been entitled.
Losing commercial rebate dollars has an immediate consequence for health plans and employers. The plan no longer benefits from a lower, negotiated price, in turn raising premiums for commercially insured enrollees.
While these losses may have once been minimal, the explosive growth of the 340B program means that lost rebates are now consequential. A 2024 analysis found that more than $5 billion in rebates are lost to the 340B program.
A similar phenomenon affects state Medicaid programs. While about half of states have laws ensuring that discounts accrue to Medicaid and not 340B providers, the remaining states – which use managed care to run their Medicaid programs and do not carve out 340B prescriptions – face much the same situation as commercial payers. When a Medicaid patient in these plans receives a prescription from a 340B hospital or clinic, the provider receives the discount, and the Medicaid program must reimburse the full list price.
States can shift the way discounts flow through the system to ensure that the Medicaid program and not the hospital or clinic receives the discount. Such an effort is underway in Indiana. Still, such a choice only highlights the public policy dilemma. While Medicaid programs benefit from the financial flexibility of receiving rebates directly, allowing 340B discounts to flow to 340B providers helps ensure the financial viability of the hospitals and clinics that care for Medicaid patients.
Towards Greater Transparency
A dangerous narrative persists that because the 340B program is not formally funded by the government or private payers, it imposes no costs on the system. Such a perspective ignores impacts both direct and indirect. The growth of 340B directly lowers rebate revenue, thereby putting upward pressure on premiums. And 340B-related consolidation and anticompetitive effects create the conditions for increasing pricing system-wide. Resolving these dilemmas requires three common-sense changes in how the program operates.
First, manufacturers should receive claims-level data to help flag 340B claims at the source, identifying duplicate discounts before overlapping payments are made. This step need not be the responsibility of the manufacturers; a neutral clearinghouse – established with either statutory authority or broad stakeholder buy-in -- could provide this function.
Second, with this foundation in place, data on 340B claims should be made available for researchers and policymakers so that pharmacy claims coded as 340B can be analyzed by channel.
Third, this basic level of transparency should be paired with new reporting requirements, such as those proposed by the American College of Physicians that make clear how 340B funds are used by providers. The goal would be to ensure that the benefits are flowing to patients in a way that is direct and measurable.
340B resources represent real transfers of wealth, borne by patients across the system, which should be accounted for in discussions about the future of the program. Transparency measures are not an end unto themselves but rather a means to achieve greater understanding of the way that 340B money and medicines move through the healthcare system. Though a more robust set of interventions, such as tightening provider eligibility criteria, may warrant attention, transparency is a precondition for much of this policymaking.
